DE602006005084D1 - Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen - Google Patents

Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen

Info

Publication number
DE602006005084D1
DE602006005084D1 DE200660005084 DE602006005084T DE602006005084D1 DE 602006005084 D1 DE602006005084 D1 DE 602006005084D1 DE 200660005084 DE200660005084 DE 200660005084 DE 602006005084 T DE602006005084 T DE 602006005084T DE 602006005084 D1 DE602006005084 D1 DE 602006005084D1
Authority
DE
Germany
Prior art keywords
predicting
prohibitin
preventing resistance
taxoid compounds
taxoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE200660005084
Other languages
English (en)
Inventor
Bruce R Zetter
Sabarni K Chatterjee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Original Assignee
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp filed Critical Childrens Medical Center Corp
Publication of DE602006005084D1 publication Critical patent/DE602006005084D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y205/00Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01018Glutathione transferase (2.5.1.18)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/44Multiple drug resistance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer
DE200660005084 2005-11-17 2006-11-17 Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen Active DE602006005084D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73765305P 2005-11-17 2005-11-17
PCT/US2006/044819 WO2007061922A2 (en) 2005-11-17 2006-11-17 Methods to predict and prevent resistance to taxoid compounds

Publications (1)

Publication Number Publication Date
DE602006005084D1 true DE602006005084D1 (de) 2009-03-19

Family

ID=38067807

Family Applications (1)

Application Number Title Priority Date Filing Date
DE200660005084 Active DE602006005084D1 (de) 2005-11-17 2006-11-17 Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen

Country Status (7)

Country Link
US (3) US8148086B2 (de)
EP (1) EP1948213B1 (de)
AT (1) ATE422162T1 (de)
AU (1) AU2006318722A1 (de)
CA (1) CA2630214A1 (de)
DE (1) DE602006005084D1 (de)
WO (1) WO2007061922A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148086B2 (en) 2005-11-17 2012-04-03 Children's Medical Center Corporatioin Methods to predict and prevent resistance to taxoid compounds
US20090258020A1 (en) * 2008-01-07 2009-10-15 Patrys Limited Antibody designated barb3, barb3 related antibodies, and methods of making and using same
US20140356285A1 (en) * 2011-09-23 2014-12-04 The Board Of Regents Of The University Of Texas System Compositions and methods related to tissue targeting
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
TWI715594B (zh) * 2015-06-24 2021-01-11 日商日東電工股份有限公司 用於麩胱甘肽S轉移酶Pi(GST-π)基因調控之RNA干擾劑
EP3373971A4 (de) * 2015-11-13 2019-09-25 Massachusetts Institute of Technology Verfahren und zusammensetzungen zur detektion und modulation von krebszellen
KR101854291B1 (ko) 2016-02-16 2018-05-03 전남대학교산학협력단 프로히비틴 단백질에 대한 항체를 포함하는 혈액암 진단용 조성물 및 이를 포함하는 혈액암 진단용 키트
JP6899201B2 (ja) * 2016-06-23 2021-07-07 日東電工株式会社 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物
US10313019B2 (en) * 2016-07-01 2019-06-04 Luxtera, Inc. Method and system for redundant light sources by utilizing two inputs of an integrated modulator
EP3755814A4 (de) 2018-02-23 2021-12-01 Cornell University Test zum nachweis von androgenrezeptorvarianten

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241144A1 (en) * 2004-09-23 2008-10-02 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften, E. V. Prohibitin as Target for Cancer Therapy
CA2613290A1 (en) * 2005-05-27 2007-05-24 Aurelium Biopharma Inc. Focused microarray and methods of diagnosing chemotherapeutic drug resistance in a cancer cell
US20070122830A1 (en) * 2005-11-10 2007-05-31 Aurelium Biopharma Inc. Prohibitin-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
US8148086B2 (en) 2005-11-17 2012-04-03 Children's Medical Center Corporatioin Methods to predict and prevent resistance to taxoid compounds

Also Published As

Publication number Publication date
WO2007061922A2 (en) 2007-05-31
EP1948213A2 (de) 2008-07-30
US20160011211A1 (en) 2016-01-14
US20090312405A1 (en) 2009-12-17
US20130028885A1 (en) 2013-01-31
US9151758B2 (en) 2015-10-06
ATE422162T1 (de) 2009-02-15
AU2006318722A1 (en) 2007-05-31
EP1948213B1 (de) 2009-02-04
CA2630214A1 (en) 2007-05-31
US8148086B2 (en) 2012-04-03
WO2007061922A3 (en) 2007-10-18

Similar Documents

Publication Publication Date Title
DE602006005084D1 (de) Verfahren zur vorhersage und verhinderung der resistenz gegen taxoid-verbindungen
CY1125027T1 (el) Μονοκλωνικα αντισωματα κατα κλαουδινης-18 για τη θεραπεια του καρκινου
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
ATE547102T1 (de) Carbolin-derivate zur behandlung von krebs
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA200970738A1 (ru) Ингибиторы активности akt
CY1108092T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου με την αναστολη της κινασης aurora
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
ATE483705T1 (de) (lh-ind0l-7-yl)-(pyrimidin-2 -yl-amino) methanon derivate und verwandte verbindungen als igf-rl inhibitoren zur behandlung von krebs
ATE461220T1 (de) Anti-egfr-antikörper
CL2009001274A1 (es) Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer.
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
EA200900571A1 (ru) Композиции chk1 ингибиторов
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
BRPI0908635A8 (pt) composto, composição farmacêutica e método de tratamento de câncer
ATE502025T1 (de) Arylcarboxamide und ihre verwendung als antitumormittel
EA201170344A1 (ru) Азаиндольные ингибиторы iap
TW200716132A (en) Novel chemical compounds

Legal Events

Date Code Title Description
8364 No opposition during term of opposition